Format

Send to

Choose Destination
Expert Opin Drug Saf. 2019 Jun;18(6):497-509. doi: 10.1080/14740338.2019.1614165. Epub 2019 May 22.

Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study.

Author information

1
a Unit of Clinical Pharmacology , A.O.U. Policlinico "G. Martino" , Messina , Italy.
2
b Department of Biomedical and Dental Sciences and Morpho-functional Imaging , University of Messina , Messina , Italy.
3
c Department of Epidemiology , Lazio Regional Health Service , Roma , Italy.
4
d Health Department of Sicily , Sicilian Regional Centre of Pharmacovigilance , Palermo , Italy.
5
e Division of Rheumatology , University and IRCCS Policlinico S. Matteo Foundation , Pavia , Italy.
6
f Department of Pediatrics , University of Milano-Bicocca, Ospedale S Gerardo , Monza , Italy.
7
g Department of Clinical and Experimental Medicine , A.O.U. Policlinico "G. Martino" , Messina , Italy.
8
h Neonatal and Pediatric Intensive Care Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi" , University of Messina , Messina , Italy.
9
i Department of Experimental Medicine , University of Campania "Vanvitelli", and Campania Regional Center of Pharmacovigilance and Pharmacoepidemiology , Naples , Italy.
10
j Research Centre on Public Health (CESP) , University of Milan-Bicocca , Monza , Italy.
11
k Department of Pharmacy , Palermo Local Health Unit , Palermo , Italy.
12
l Epidemiologic Observatory of the Sicily Regional Health Service , Palermo , Italy.

Abstract

Introduction: Orphan drugs are medicines intended to treat, prevent, or diagnose a rare and serious condition. The collection of pre-marketing safety and efficacy data for orphan drugs is very challenging for several reasons related to the rarity of the diseases. This highlights the need for robust post-marketing evidence generation. Real-world data sources, such as claims databases, electronic healthcare records, and disease and drug registers, have an important role in studying orphan drugs. The availability and usefulness of such resources vary from country to country. Areas covered: A detailed description of the available real-world data sources and their contribution to generating post-marketing evidence on orphan drug benefit-risk profile in Italy is provided. Expert opinion: Despite their considerable potential for rare disease research, the available Italian data sources are currently under-used and require further harmonization of data collection. The establishment of large structured and integrated nationwide data sources, tailored to respond to both research as well as regulatory requirements, is necessary to provide clinically useful information on orphan drugs as well. Such data sources should also be more accessible at the loco-regional, national and international level.

KEYWORDS:

Italy; Rare diseases; orphan drugs; real-world data

PMID:
31059293
DOI:
10.1080/14740338.2019.1614165
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center